Turtle Creek Wealth Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.12M Buy
39,116
+2,246
+6% +$59.7K 0.06% 162
2026
Q2
$888K Buy
36,870
+5,787
+19% +$151K 0.05% 175
2026
Q1
$873K Buy
31,083
+4,350
+16% +$116K 0.07% 155
2025
Q4
$666K Sell
26,733
-654
-2% -$16.5K 0.05% 200
2025
Q3
$698K Buy
27,387
+10,935
+66% +$270K 0.06% 174
2025
Q2
$399K Buy
+16,452
New +$384K 0.05% 191
2025
Q1
– Sell
-10,394
Closed -$276K – 125
2024
Q4
$276K Buy
10,394
+1,326
+15% +$36K 0.06% 71
2024
Q3
$262K Buy
+9,068
New +$265K 0.05% 152
2024
Q1
– Sell
-3,380
Closed -$97.3K – 642
2023
Q4
$97.3K Buy
+3,380
New +$102K 0.03% 203

Other funds holding PFE

Turtle Creek Wealth Advisors's PFE Position: Q3 2026 in Review

Turtle Creek Wealth Advisors increased its Pfizer (PFE) stake by 6.1% in Q3 2026, buying an estimated $59.7K and bringing the position to 39,116 shares worth $1.12M. The position accounts for 0.06% of the portfolio, ranked #162.

Turtle Creek Wealth Advisors first reported a position in PFE in Q4 2023 and has held it in 9 quarters since. 2,640 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Turtle Creek Wealth Advisors held 39,116 shares of Pfizer worth $1.12M as of Q3 2026.
  • Turtle Creek Wealth Advisors bought 2,246 Pfizer shares in Q3 2026, an estimated $59.7K.
  • Pfizer made up 0.06% of Turtle Creek Wealth Advisors's portfolio in Q3 2026, its #162 holding.
  • Turtle Creek Wealth Advisors first reported a position in Pfizer in Q4 2023 and has held it in 9 quarters since.
  • 2,640 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Turtle Creek Wealth Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.